Cargando…

Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Detalles Bibliográficos
Autores principales:	Bruni, Alessio, Scotti, Vieri, Borghetti, Paolo, Vagge, Stefano, Cozzi, Salvatore, D’Angelo, Elisa, Giaj Levra, Niccolò, Fozza, Alessandra, Taraborrelli, Maria, Piperno, Gaia, Vanoni, Valentina, Sepulcri, Matteo, Trovò, Marco, Nardone, Valerio, Lattanzi, Elisabetta, Bou Selman, Said, Bertolini, Federica, Franceschini, Davide, Agustoni, Francesco, Jereczek-Fossa, Barbara Alicja, Magrini, Stefano Maria, Livi, Lorenzo, Lohr, Frank, Filippi, Andrea Riccardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637883/ https://www.ncbi.nlm.nih.gov/pubmed/34869046 http://dx.doi.org/10.3389/fonc.2021.802949

Ejemplares similares

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
por: Bruni, Alessio, et al.
Publicado: (2021)

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
por: Borghetti, Paolo, et al.
Publicado: (2022)

Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic
por: Magrini, Stefano Maria, et al.
Publicado: (2020)

Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter Prospective Observational TRENDS Study
por: Cozzi, Salvatore, et al.
Publicado: (2023)

Novel Harmonization Method for Multi-Centric Radiomic Studies in Non-Small Cell Lung Cancer
por: Bertolini, Marco, et al.
Publicado: (2022)

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach
por: Bruni, Alessio, et al.
Publicado: (2019)

The role of postoperative radiotherapy for thymomas: a multicentric retrospective evaluation from three Italian centers and review of the literature
por: Bruni, Alessio, et al.
Publicado: (2020)

Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis
por: Gobbini, Elisa, et al.
Publicado: (2021)

Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab
por: Guerini, Andrea Emanuele, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia
por: Molon, Giulio, et al.
Publicado: (2022)

Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?
por: Nicosia, Luca, et al.
Publicado: (2020)

The Italian Association of Radiotherapy and Oncology Recommendation for Breast Tumor Recurrence: Grades of Recommendation, Assessment, Development and Evaluation Criteria
por: Bottero, Marta, et al.
Publicado: (2021)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

The potential role of SPECT/CT in the clinical management of COVID-19 lung cancer patients undergoing radiotherapy
por: Borghetti, Paolo, et al.
Publicado: (2021)

Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer
por: Pierret, Thomas, et al.
Publicado: (2020)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Hypofractionated Postoperative Radiotherapy in Prostate Cancer with Ialuril Soft Gels(®): Toxicity and Efficacy Analysis on a Retrospective Series of 305 Patients
por: Nicosia, Luca, et al.
Publicado: (2022)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) consensus conference on sarcoma interventional radiotherapy (brachytherapy) endorsed by AIRO (Italian Association of Radiotherapy and Clinical Oncology)
por: Tagliaferri, Luca, et al.
Publicado: (2020)

COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)()
por: Jereczek-Fossa, Barbara Alicja, et al.
Publicado: (2020)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Phimosis: A rare complication of immunotherapy with durvalumab
por: Vázquez-Lavista, Luis Gabriel, et al.
Publicado: (2020)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
por: Patel, Shivani, et al.
Publicado: (2019)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
por: Sanderson, Emma, et al.
Publicado: (2020)

Acquired amegakaryocytic thrombocytopenia after durvalumab administration
por: Suyama, Takahiro, et al.
Publicado: (2021)

Durvalumab: Immune-related pneumonitis: case report
Publicado: (2021)

Skin puckering and edema during durvalumab therapy
por: Olamiju, Brianna, et al.
Publicado: (2020)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Durvalumab/elasomeran: Immune thrombocytopenia: case report
Publicado: (2022)

Strongyloides—An uncommon cause of eosinophilia whilst on durvalumab
por: Quah, Gaik Tin, et al.
Publicado: (2022)

Durvalumab-associated generalized morphea with overlapping vitiligo
por: Martel, Julianna, et al.
Publicado: (2022)

Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab
por: Kreze, Alexander, et al.
Publicado: (2022)

Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_62fhprr9r7gemvus6i7fk48hjp